BPI 520105
Alternative Names: BPI-520105Latest Information Update: 03 Jul 2024
At a glance
- Originator Betta Pharmaceuticals Co Ltd
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 14 Jun 2024 Betta Pharmaceuticals has patent protection for BPI 520105 (Betta Pharmaceuticals pipeline, June 2024)
- 14 Jun 2024 Phase-I clinical trials in Solid tumours (PO) in China prior to June 2024, (Betta Pharmaceuticals pipeline, June 2024)
- 05 Apr 2024 Pharmacodynamics and Pharmacokinetic data from a preclinical trial in Non small cell lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research